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Abstract
Around 50% of cancer patients will require radiotherapy (RT) and 10–15% of 
these patients could be eligible for proton beam radiotherapy (PBT). Dosimetric 
advantages are undeniable, mainly in pediatric and reirradiation scenarios. Though, 
PBT facilities are scarce worldwide and the IAEA has reported 116 functional 
particle facilities, of which 98 are PBT, virtually absent in low- and middle-income 
countries (LMIC). The Latin America and Caribbean region represent a unique 
opportunity for a PBT center, as there are currently no functional facilities and 
current RT needs are significant. The challenges can be summarized as high initial 
investment and maintenance, geographic coverage, required baseline technol-
ogy and certification, over-optimistic workload, unclear rates and reimburse-
ment, unmet business plan and revenue expectations, and lack of trained human 
resources. Investment costs for a PBT facility are estimated to be at around 140 
million euros; therefore, this seems unsuitable for LMIC. Mexico’s geographical 
advantage, GDP, baseline technologies and high demand for RT makes it an ideal 
candidate. Nevertheless, a PBT center would account for a third of Mexico’s annual 
health expenditure for 2020. Enormous efforts must be made by both the private 
sector and governmental authorities to provide funding.
Keywords: proton therapy, cost-effectiveness, low-to-middle-income countries, 
infrastructure
1. Introduction
Radiotherapy (RT) is an integral component of contemporary cancer treat-
ment, both as curative and palliative therapy. Around 50% of patients will, at some 
point during their cancer history, require RT. Its contribution to cancer survival 
is estimated at around 40% versus 49% for surgery and 11% for systemic treat-
ment modalities. [1] In the past decade, ongoing research in systemic therapies has 
broadened the indications for RT, since as long-term survival increases so does the 
prevalence of the disease. Oligometastatic cancer recurrence is increasingly man-
aged with RT, as well as oligoprogressive disease. This in addition to its more com-
mon applications, such as local control in curable or metastatic settings. However, 
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dose-limiting toxicity remains the main problem for RT, especially for in-field 
recurrences where reirradiation is a bigger concern.
Proton beam radiotherapy (PBT) is a novel technique with endless possibilities. 
Different simulation models have estimated that 10–15% of all radiated patients 
from various European countries could be eligible for PBT, but only less than 
1% receive it. [2] Since toxicity and dosimetry advantages are undeniable, and 
although there is still scarce clinical practice, indications and applications are on 
the rise mainly in pediatric and reirradiation scenarios, without excluding common 
indications for radiation treatments, especially when dose constraints are an issue. 
Still, PBT remains non-existent in Latin America and virtually absent in low- and 
middle-income countries (LMIC). The following chapter will focus on how a 
PBT can be suitable for proven clinical indications in LMIC, particularly in Latin 
America and Mexico, where cancer and epidemiology registries—although insuf-
ficient—present a broader view of current RT needs when compared to other LMIC 
across Africa and Asia. A general overview of the facts and realities of RT, as well as 
the challenges and limitations expected for a proton facility in these countries, will 
be presented.
The Latin America and Caribbean (LAC) region represents a unique clinical  
opportunity for a proton radiation therapy center, as there are currently no 
functional facilities and because current radiotherapy needs are significant. 
Nevertheless, auxiliary diagnostic facilities required for a functional PBT center, 
such as computed tomography (CT), positron emission tomography (PET), 
magnetic resonance imaging (MRI) and pathology departments, although insuf-
ficient, are found in some LAC cities, meeting the highest quality requirements 
and the most rigorous international certifications. There is an upcoming PBT 
center in Buenos Aires, Argentina with operations due to start in 2022. Even with 
this center, availability for this type of treatment is evidently not enough for the 
629 million inhabitants living/distributed in the 192 million km2 of Latin American 
territory. [3]
2. Proton therapy in low- and middle-income countries
2.1 Facts and reality
According to the IAEA Directory of Radiotherapy Centres, there are 116 
functional proton/ion facilities (107 in high-income countries, 8 in upper-
middle-income countries and 1 in LMIC) around the world, out of which 98 are 
PBT. Most are located in high-income countries in North America, Europe and 
Asia, countries that coincidentally have the highest number of photon radio-
therapy equipment, and none in LAC. [4] Figure 1 shows available PBT facilities 
according to their operation status. Even LAC has RT available only in 70% of its 
countries, with approximately 1 megavoltage machine per 650,000 inhabitants. 
Distribution varies according to income groups, creating an unequal environment 
for adequate cancer care, particularly from a radiotherapy standpoint. [5]
Cancer accounts for 10% of the global healthcare budget, out of which RT takes 
up only about 5%; therefore, RT expenditure is about 0.25–1% of the total healthcare 
budget. [6] This represents a very small fraction of the total healthcare budget if we 
consider that up to 25% of the population is expected to go through radiation treat-
ment at some point in their life. [7] Although RT is regarded as the cheapest cancer 
treatment modality, limited resources are available in Latin America due to absence 
of domestic and international funding. Approximately 90% of the population in 
these countries will lack access to RT.
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Insufficient detailed information about attainability for radiotherapy and 
auxiliary diagnostic tools in LMIC is a constant. Currently very few countries in LAC 
have submitted recent data. Thus, planning for a PBT center requires data regard-
ing general availability, not only for radiotherapy but also for auxiliary diagnostic 
tools, such as PET, MRI, CT scans and pathology laboratories, many of which are 
either partially or completely unavailable across the LAC region. Developing a PBT 
center with full access to all therapeutic and diagnostic tools involved in proton 
therapy must therefore be contemplated in at least one of the main cities of the 
region; otherwise, PBT center usage could be suboptimal. LAC presents a complex 
paradox, where most of childhood cancer and reirradiation scenario candidates for 
PBT are much more frequent than in developed countries—where most PBT centers 
exist—but is simultaneously the region facing the most difficulties for a functional 
PBT center, not due to the obvious economic challenges, but because of the lack of 
complementary and auxiliary tools required for it.
Another issue is that currently around 8% of LAC residents are 65 years or older, 
which represents the population with the highest risk for malignant neoplasms. By 
2050, this figure is expected to double to 17.5% and to exceed 30% by the end of 
the century. In 2018, this represented over 1.3 million new cancer cases and over 
660,000 cancer-related deaths; therefore, at least twice this number will reflect 
cancer deaths by 2050 unless international efforts to reduce mortality are effectively 
implemented. [8]
2.1.1  Adult tumors suitable for PBT in Latin America and their relevance for a 
proton facility
The LAC region encompasses 33 countries and 15 dependencies or territories 
with a total population of 646 million in 2019. [9] With a combined gross domes-
tic product (GDP) of United States dollars (USD) 5.7 trillion, LAC is a region of 
growing importance to the world economy. [10, 11] GDP per capita ranges from 
USD 754 in Haiti to USD 85,477 in the Cayman Islands. Haiti is considered the only 
low-income country in the region; 7%, 49% and 41% are considered lower-middle-, 
upper-middle- and high-income countries, respectively. [12] According to Bishr 
Figure 1. 
Available proton therapy facilities in clinical operation and under construction.
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et al., there is a total of 593 RT centers in 28 countries, with up to 983 megavolt-
age machines, of which 23.9% are telecobalt machines. Twelve countries (30%), 
containing 2% of the LAC population (estimated population of 12.5 million), lack 
RT facilities. [13]
Although the number of needed radiotherapy machines varies between reports 
and despite underestimation due to lack of cancer registries, the overall conclu-
sion is that around 50% of cases requiring radiotherapy in LMIC never receive 
treatment, and this goes up to 90% in low-income countries. [7] Additionally, the 
economic burden of lost productivity due to morbidity and premature death from 
cancer accounts for nearly 60% of the total economic burden associated with cancer 
in European Union countries. [14]
2.1.2 Pediatric tumors in Latin America and their relevance for a proton facility
Although pediatric cancers represent 10–13% of patients treated with PBT in 
the US, PBT has proven clinical applications, especially for pediatric brain tumors 
since important toxicities such as growth deficiencies, hearing loss, intelligence 
quotient impairment, learning disabilities and secondary malignant neoplasms will 
potentially be avoided in childhood survivors. Among potential tumors treated with 
PBT, medulloblastoma and other pediatric central nervous system (CNS) malignan-
cies in people under 21 are highly prevalent in LAC. LMIC countries have younger 
populations; for example, according to UNICEF, there are over 193 million minors 
registered in LAC. [15] Therefore, the expected number of children with cancer is 
larger. It is estimated that around 84% of childhood cancer occurs in these coun-
tries, simply because nearly 90% of the world’s children population lives in LMIC. 
Moreover, 45% suffer from child poverty, which limits their access to RT.
GLOBOCAN estimates the incidence of childhood cancer varies between 50 and 
200 cases per million children each year in different LMIC. However, this data is 
not reliable due to many undiagnosed childhood cancers, especially in rural areas 
of LAC, where diagnostic tools, such as MRI or even CT scanning, are not available 
[16]. Under-recording is another main issue since LMIC have weaker epidemiology 
networks and death certificates may be incomplete or absent. All of these factors 
contribute to inaccurate data.
Childhood cancer survival rates vary widely by region, particularly in LMIC, 
where lack of access to diagnoses is just the tip of the iceberg. Access to optimal 
treatments is often limited to private and selected tertiary public institutions. These 
out-of-pocket expenditures are often prohibitive for most of the LMIC population 
and, among many other factors, are essential components for this foreboding result. 
A simulation-based analysis for global childhood cancer survival estimates shows 
large variation by region, ranging from 8.1% (4.4–13.7) in low-income countries in 
Eastern Africa to 83% in high-income countries in North America, placing Latin 
America central nervous system cancer survival estimates at around 50%. [17]
2.1.3 Advantages and limitations of PBT
PBT has been used for almost seven decades. Even so, indications of PBT for 
cancer treatment have had an alarmingly slow development, often being displaced 
by other radiotherapy techniques, such as stereotactic body RT (SBRT) or intensity-
modulated RT (IMRT) /volumetric arc therapy (VMAT). PBT has an important 
and undeniable radiobiological advantage over SBRT and VMAT techniques, [18] 
since it significantly reduces the absorbed dose by normal tissue and lowers whole 
body integral radiation doses due to the requirement of fewer treatment fields, 
[14, 19] which means there is overall less acute and late toxicity. This has been 
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proven in multiple clinical trials, particularly in pediatric cancer and specific adult 
malignancies (skull base, head and neck, hepatocellular, central nervous system, 
breast, lung, prostate, testicular and ocular tumors), among other fewer common 
scenarios, such as reirradiation, where it allows for dose escalation in patients who 
otherwise would not be optimal candidates for photon therapy. [2]
Challenges for investment in particle therapy treatment centers reported by the 
European Investment Bank can be summarized in a) PBT is currently indicated for 
only a small number of cancers; b) treatment is very costly and time consuming;  
c) geographic coverage; d) limited research activity. Main issues for project imple-
mentation include a) delays and problems with technology specifications and cer-
tification; b) overflow of patients seeking treatment and over-optimistic workload; 
c) unclear rates and reimbursement schemes; d) unmet business plan and revenue 
expectations; e) limited number of trained human resources. Surprisingly, limitations 
for PBT are mainly economical, not only because of the high initial investment but 
also due to the yearly increases in the cost of cancer care, often above inflation rates. 
This raises the concern that a PBT facility that was once sustainable will not be so in 
the future due to operational costs, quality assurance, maintenance and continuous 
training and/or medical education. Lack of high-quality clinical data on outcome and 
long-term toxicity for PBT contributes to mistrust, but this is a symptom that reflects 
lack of investment, not a limitation of PBT per se. [20]
2.1.4 Realities of radiotherapy attainability in Latin America and/or Mexico
Starting a PBT center is an enormous challenge and many variables should be 
accounted for, not only the obvious limitations such as economic capabilities and 
preexisting infrastructure. But also more subjective and complex variables, such 
as amenable workforce, solid governmental facilities for diagnosis and oncologic 
treatment like a national cancer institute, national and international private sector 
funding, and an organized radiation oncologist society committed to and involved 
in providing all necessary means for a comprehensive workforce network across the 
country or the whole LAC region for patient recruitment and referral.
Viability of a PBT center is only possible if a continuous flow of patients is 
guaranteed, either from locoregional cases or from a referral-based system, and 
this can only be done by few LAC countries. Based on published information about 
current demographics, radiotherapy capabilities and diagnostic workup auxiliaries, 
this might only be possible in few countries. Economic capabilities are fundamental 
for such type of investment. Even with international support, only cities with a high 
population and GDP should be considered. Table 1 ranks the 5 top cities by popula-
tion and GDP amenable for any PBT projects. As stated before, there is already an 
ongoing PBT project running in Buenos Aires, Argentina.
It is estimated that two thirds of cancer-related deaths will occur in LMIC and 
treatment related-morbidity and mortality cause an enormous economic burden, 
especially in developing countries. Taking into account a PBT center is projected to 
start soon in Argentina, geographic location, gross domestic income, RT capabilities 
and diagnostic auxiliary tools available, a following PBT center could be feasible in 
Mexico. Particularly in the metropolitan area, where most oncology centers in the 
country are located. Mexico is currently the 14th most powerful world economy and 
11th in purchasing power parity, second biggest economy in LAC and 4th in the con-
tinent, and is currently classified as an upper-middle-income country with a median 
age of 28 years old, 7.3% of its population being 65 years or older. [12, 21] Mexico is 
an exceptionally young country for its economic capabilities, with an incidence of 
childhood and teenage cancer of 89.6 per million inhabitants (111.4 in children aged 
0–9 and 68.1 for teenagers aged 10–18) in 2017 and a prevalence of 18,000 annual 
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cases in persons under 18 years of age. [22] The estimated incidence and prevalence 
of all cancers was 195,499 and 530,602 in 2020, respectively. [23] A busy PBT center 
is feasible. Mexican radiotherapy demographics have been recently published and 
this information is not only crucial for any investment on PBT, but also sets a neces-
sary precedent for adequate development.
According to the Mexican radiotherapy certification board, the country lies on 
an alarmingly low density of radiotherapy facilities, with a density of 1.19 linear 
accelerators per million inhabitants. [24] Mexico stands out because of this, since 
it’s not only one of the few countries in LAC that could divert health expenditures to 
a PBT project, but it also currently has an enormous need for radiotherapy facilities. 
The need for RT centers is huge and will rise in the following years in conjunc-
tion with the increasing age of its population and the number of pediatric cancer 
patients requiring RT (due to its high pediatric population).
2.2 Challenges
2.2.1 Cost evaluation
Van Dyk (2017) evaluated the annual cost of 4 fully independent centers with 
two linear accelerators each. They reported that capital costs, operational costs per 
year and cost per treatment course in high-income countries (HIC) are approxi-
mately $41,175,000, $18,309,00 and $5,350, respectively; whereas for LMIC, it’s 
$32,035,000, $6,911,000 and $2,020, respectively. [25] In 2003, Goiten estimated 
that particle therapy was about 2.4 times more expensive than most sophisticated 
RT techniques, and that this could be reduced to 1.7–2.1 over a decade. [26] The 
investment costs are estimated to be about 140 million euros or 150–200 million 
dollars for a 4 to 5-room PBT facility and 40 million for a single-room center, which 
represent a more affordable option even for high-income countries [26, 27]. The 
former represents a small, but important, fraction of Mexico’s health expenditure 
(which is approximately 31,700 million USD in 2020) [28].






































Abbreviations: B: billion; GDP: gross domestic product; M: million; PPP: purchasing power parity; US$: american 
dollars.
Table 1. 
Top 5 cities by population and GDP amenable for any PBT projects. 
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Lifespan of a PBT facility should also be considered. Although the cost of a 4- or 
5-room PBT center can reach several hundred million dollars, a large portion of the 
cost is attributable to the cyclotron or synchrotron and the huge rotational gantries 
with a lifespan of more than 30 years. Which is significantly longer than the 7-year 
average lifespan of a linear accelerator. The direct cost of a modern 4-gantry PBT 
center is similar to that of a linear accelerator facility with 16 machines over its 
30-year lifespan (4 linear accelerators replaced 3 or 4 times over this period). [29].
Several US PBT centers had to accept a reference price as payment for PBT 
instead of no payment or coverage. In this case, payment is made based on the 
next most expensive alternative, which does not cover the real cost of delivering 
the treatment. [30] Additionally, some payers are complaining that they pay for 
a therapy with no clear evidence of benefit. [31] A focus only on direct up-front 
costs at the time of the treatment is inaccurate because the indirect costs of manag-
ing and surviving with the late adverse effects of radiotherapy could be reduced 
significantly or even completely with PBT. [29].
2.2.2 Cost-effectiveness analysis and limitations
Investment in high-cost RT facilities will also lead to an increase of the mean 
treatment cost; however, the cost-effectiveness of PBT may improve if the rate of 
patients with indications expected to benefit from this innovation increases. [32] 
PBT cost-effectiveness studies should include costs associated with intervention 
and secondary benefit comparisons. In summary, all potential costs saved from 
morbidity and/or mortality reduction versus all possible expenses should be consid-
ered. It is very difficult to include and assess every direct and indirect cost related to 
intervention. This should include construction of the PBT facilities, operational or 
procedural cost (personnel costs, electricity and maintenance, beam delivery time, 
number of patients treated). In addition, it should consider potential toxicities and 
their related costs, such as support medication and/or hospitalization related to 
RT-induced toxicities, both potentially more frequent in patients with a long life 
expectancy, close anatomical relationships to organs at risk (OAR), advanced tumor 
stage, histopathology and pre-existing comorbidities. Others factors that affect 
cost-effectiveness are treatment volume, treatment fields, treatment duration, total 
dose and fractionation. [2] A country’s health system organization also influences 
economic cost. Since public (complete coverage versus adjusted-socioeconomical 
payment) and private services (with or without insurance company, and percentage 
of reimbursement) differ significantly in availability, reimbursement and cost, this 
must be considered in the analysis. And even more important is the availability of 
treatment machines.
PBT use in pediatric cancer is based on integral dose advantages of protons over 
photon RT. It modulates dosage to avoid OAR when the dose is high and OAR are 
close and with integral dose minimization. [33] Verma (2016) reported a 2.4-fold 
increase in initial cost of PBT versus conventional or IMRT in pediatric cancers. 
However, total costs of adverse effects showed an 8-fold decrease in favor of PBT. 
This yields a 2.6-fold reduction of overall costs in favor of PBT. [2] Currently, 
PBT is the most cost-effective option for several pediatric brain tumors. [34] 
Especially in craniospinal irradiation (CSI) with high dose boost requiring more 
conformation, such as in medulloblastoma, in which associated adverse effects 
related to radiotherapy are IQ decline, hearing loss and growth hormone defi-
ciency. In atypical cases, such as high-grade glioma and sarcoma or retreatment 
of spine lesions, the doses achieved treat less normal tissue and can avoid internal 
OAR better. [35, 36] Other pediatric tumors suitable for PBT are intracranial and 
skull base tumors, spine tumors, Hodgkin Lymphoma and retreatment. As such, 
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PBT is more cost-effective for pediatric cancer due to the decrease in long-term 
toxicity, long life expectancy after cancer treatment and more remaining years 
of economic-productive life. Therefore, although the number of cancers that 
are cured is generally very low, treatment of curable childhood cancer is highly 
cost-effective. Some issues to be considered include limited data, lack of long-term 
follow-up and contraindications for PBT (Wilms’ tumor classic fields, whole lung 
classic fields and palliative RT). [2] By contrast, a Brazilian patient volume-based 
analysis showed that PBT was not cost-effective for pediatric medulloblastoma 
treatment. [37].
Other outcomes that can be measured include total life-years gained or lost, and 
quality-adjusted life years (QALYs). [2] For pediatric brain tumor, the incremental 
cost-effectiveness ratio was $21,716 to 26,419 dollars per QALY, depending on the 
study. [34].
In adult cases, PBT as standard treatment for breast cancer has not been shown 
to be cost-effective and is associated with a minimal increase in QALYs. However, 
specific subgroups that may benefit include patients with high-risk late cardiac 
toxicity, such as left-sided tumors or internal mammary node irradiation and those 
with double baseline risk of non-radiotherapy-related cardiac disease. [34, 38] For 
locoregionally advanced non-small cell lung cancer (NSCLC), PBT increased QALYs 
compared to conformal or IMRT, and was probably more cost-effective than for 
early-stage NSCLC. [34, 39, 40] In locally advanced head and neck cancer, inten-
sity-modulated PBT (IMPT) reduces xerostomia and dysphagia rates compared to 
IMRT; however, cost was increased, [41] with an incremental cost-effectiveness 
ratio of $4,254 to 143,229 US dollars per QALY, depending on study and radia-
tion technique. [34] In another Chinese study, IMPT was more cost-effective and 
provided an extra 1.65 QALYs for paranasal sinus and nasal cavity cancers compared 
to IMRT. [42] For prostate cancer, PBT showed increased costs without increasing 
QALYs compared to IMRT; in this case, life expectancy determines cost-effective-
ness. [43] However, PBT is currently not considered medically necessary for the 
treatment of lung, prostate, breast, gastro-esophageal, hepatocellular, head and 
neck, gynecologic cancer or Hodgkin and non-Hodgkin Lymphoma. [44] A review 
of PBT concluded that no clinical data had shown superiority over advanced RT for 
treatment of central nervous system lesions. It is only medically necessary for cases 
with adjacent structures. [45] Given the excellent long-term results with PBT, it is 
considered medically necessary for the treatment of base skull and sacral chordo-
mas and chondrosarcomas, [46] and uveal melanoma due to lower local recurrence 
rate, retinopathy and cataract formation. [47] PBT is appropriate for reirradiation 
where the dose tolerance of adjacent normal structures would be exceeded with 
conformal or IMRT. [44].
Limitations of cost-effectiveness analyses are short-term follow-up of clinical 
and toxicity evidence, and lack of standard indications. Therefore, a subgroup of 
patients that will clinically benefit and gain most QALYs may be identified for an 
adequate distribution of limited access and availability of PBT facilities.
2.2.3 Human resources
As currently there are no functional PBT centers in LAC, adequate training 
for radiation oncologists, medical physicists, dosimetrists and radiation therapy 
technicians is imperative. Although this topic is popular in medical conferences and 
webinars, the lack of clinical experience is an issue. If a PBT center is considered 
for LAC, training in all levels of attention will be necessary and this represents 
an enormous challenge by itself since long term fellowships are required, at least 
for physicists and radiation oncologists. Periodic supervision from experienced 
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personal or remote assistant and continuous medical education are two alternatives 
if intercountry fellowships are not feasible. [48].
2.2.4 Technical needs and limitations
PBT project management requires planning (construction design, permits, 
functional set-up), implementation (regulatory frame, technical expertise during 
construction) and operation (treatment planning time, patient logistics, nuclear 
safety, business plan, financial sustainability). Current PBT facilities require a space 
the size of a football field. This space is unavailable at or near the main hospitals and 
could be highly expensive in many capital cities. Therefore, future PBT units that 
are smaller (single-room PBT), more efficient and less expensive (even as low as 
$30 million dollars) are expected. [49].
The margins for protons are larger due to range uncertainties, which contribute 
to less conformality and larger higher dose volumes that include nearest OAR. 
Techniques to reduce clinical-to-planning target volume (CTV-to-PTV) margin 
include beam-specific PTV and in-vivo range verification; however, this approach 
is more expensive. [50, 51] Another limitation is image guidance and adaptive 
radiotherapy, since this modern technology is lacking in most PBT facilities. [2] 
Daily reproducibility, setup and anatomical changes are important determinants of 
dose distribution and thus in tumor control and complications. The treatment time 
per fraction with proton therapy is longer than for IMRT (22 versus 14 minutes). 
[52] The ideal PBT facility should have daily volumetric imaging for correct patient 
setup and identification of anatomical changes, adaptative replanning to compen-
sate variations and setup with respiratory motion management. [53] It is expected 
that advances will give rise to more compact PBT facilities (1 or 2 treatment rooms) 
with volumetric image guidance and with a lower cost over time. [2].
2.2.5 Initial investment
PBT has been approved for cancer treatment by the FDA since 1988. Uniform 
federal government regulations with rigorous evaluation of useful and vital versus 
inefficient and unworthy technology are necessary since uncontrolled and unregu-
lated healthcare spending on new technology without adequate determination of its 
effectiveness will eat up funds that could be spent efficiently. It should be consid-
ered that private insurers have declined to reimburse PBT for common cancer with 
no proven benefits compared to other modern techniques.
3. Conclusions
Currently there are virtually no PBT centers in LMIC, and none in LAC. 
Disparities on PBT distribution around the globe go further than just the obvi-
ous—lack of appropriate oncological treatments to alleviate human suffering—but 
are partially responsible for the slow development of PBT worldwide. At present, 
most patients amenable for PBT treatments are in LMIC countries, and clinical 
trials has been halted at least partially because of a lack of recruitment. There is 
a negative paradox, wherein patients in need of PBT have no access to it and PBT 
centers around the world with all dosimetric advantages represent less than 1% of 
all RT treatments. However, a PBT center in any LMIC is economically unviable and 
requires extensive sociodemographic studies. Mexico could be a strong candidate, 
not only due to its geographical advantages and total population, but because of its 
exceptionally young population for its economical capabilities, detailed published 
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